恩替诺特

恩替诺特，Entinostat，Cas号 209783-80-2，纯度: 99.81%，是一种 HDAC class I 选择性抑制剂，抑制 HDAC1、HDAC2 和 HDAC3 (IC50=243/453/248 nM)，具有口服活性。更多视频请关注视频号【艾维缔】。哔哩哔哩【IVDSHOW】。抖音【军哥聊表观】。

关键词

恩替诺特

所属分类

抑制剂

目录号

T6233

获取报价

猜你喜欢

产品描述
产品组分
文件资源
营销中心
注意事项
FAQ
文献追踪

恩替诺特，Entinostat (MS-275) 是一种 HDAC class I 选择性抑制剂，抑制 HDAC1、HDAC2 和 HDAC3 (IC₅₀=243/453/248 nM)，具有口服活性。Entinostat 具有抗肿瘤活性。

生物活性

产品描述	Entinostat (MS-275) is an HDAC class I selective inhibitor of HDAC1, HDAC2 and HDAC3 (IC₅₀=243/453/248 nM) with oral activity. Entinostat has antitumor activity.
靶点活性 (IC₅₀)	HDAC2:453 nM, HDAC1:0.18 μM(cell free), WSU-HN6:0.54 μM, HDAC3:0.74 μM(cell free), WSU-HN12 cells:23.31 μM
体外活性	方法: 多种肿瘤细胞用 Entinostat 处理 72 h，使用 Resazurin solution 检测细胞活力。结果: Entinostat 抑制肿瘤细胞增殖，平均 IC50 为 2.57 µM。[1] 方法: 人胰腺癌细胞 PANC-1 和 SUIT2 Clone 1 用 Entinostat (1-50 µM) 处理 72 h，使用 Western Blot 方法检测靶点蛋白表达水平。结果: Entinostat 引起细胞组蛋白 H3 乙酰化的剂量依赖性增加，对总组蛋白 H3 蛋白水平没有影响，证实了 Entinostat 抑制癌症细胞系中 HDAC 的去乙酰活性。[2]
体内活性	方法: 为检测体内抗肿瘤活性，将 Entinostat (12.5-49 mg/kg，0.05 N HCl+0.1% Tween 80) 口服给药给携带人类肿瘤异种移植物的 nude 小鼠，每周五次，持续四周。结果: 49 mg/kg的 Entinostat 对 KB-3-1、4-1St 和 St-4 肿瘤系显示出显著的抗肿瘤作用，对 Capan-1 肿瘤显示出中等的作用。24.5 mg/kg 和 12.3 mg/kg 的药物对这些肿瘤也显示出显著的效果。24.5 mg/kg 的剂量对 A2780 和 HT-29 也显著有效，对 Calu-3 也中等有效。[3]
激酶实验	The HDAC enzyme activity assay was done as described. Briefly, 40 μl HeLa cell nuclear extract, 29 μl enzyme buffer [15 mM Tris HCl pH 8.1, 0.25 mM EDTA, 250 mM NaCl, 10% (v/v) glycerol]; for recombinant HDAC isoenzymes, 0.1 mg/ml bovine serum albumin (BSA was added) and 1 μl compound were added per well of a microtiter plate. The reaction was started by addition of 30 μl substrate (Ac-NH-GGK(Ac)-AMC final 25 μM). After incubation for 90 min at 30°C, reaction was terminated by adding 25 μl stop solution (50 mM Tris HCl pH 8, 100 mM NaCl, 0.5 mg/ml trypsin, 2 μM TSA). After 40 min incubation at room temperature, fluorescence was measured using a Wallac Victor 1420 multilabel counter (Excitation 355 nm, Emission 460 nm). The HDAC1, 3, 6 and 8 assays were done with slight modifications. About 14 ng/well HDAC1, 2 ng/well HDAC3 or 10 ng/well HDAC6 were incubated with 6, 25 or 10 lM Ac-NH-GGK(Ac)-AMC, respectively, for 2 or 3 hr at 30°C. In contrast, 100 ng/well HDAC8 were incubated with 50 μM Ac-NH-RHK(Ac)K(Ac)-AMC for 3 hr at 30°C. Termination of the reaction and all further steps were done as described earlier for HeLa cell nuclear extracts. For the enzyme kinetic studies with HDAC1, selected HDAC inhibitor (around IC50 value), as well as Ac-NH-GGK(Ac)-AMC substrate (up to 100 μM) concentrations, were evaluated under standard conditions as described earlier [1].
细胞实验	Cancer cells (5 × 10^3) were seeded into each well of 96-well plates and were cultured with graded concentrations of the drugs for 3 days. The cells were stained with 0.1 mg/ml neutral red for 1 h in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μl of ethanol and 150 μl of 0.1 M Na2HPO4 was measured. The IC50 value was determined by plotting growth inhibition of the cells against the logarithm of the drug concentration [2].
动物实验	A2780 cells (9 × 10^6) grown in vitro were suspended in PBS and were injected subcutaneously into the flank of nude mouse. For the other tumor lines, KB-3-1, HCT-15, 4-1St, Calu-3, St-4, Capan-1, and HT-29, tumors were passaged several times before starting in vivo antitumor testing, and a tumor lump (2–3 mm in diameter) was transplanted subcutaneously into the flank of a nude mouse by using a trocar needle. Treatment (four or five mice in each experimental group) with the drugs was started after the tumors were confirmed to have grown in the body (tumor size, 20–100 mm3). MS-27-275 and compound 2, both dissolved with 0.05 N HCl, 0.1% Tween 80, and 5-fluorouracil (5-FU) and diluted with physiological saline, were administered orally once daily 5 days per week for 4 weeks. Tumor length and width were monitored twice weekly, and tumor volume was calculated as described [2].
别名	恩替诺特, SNDX-275, MS-275

化学信息

分子量	376.41
分子式	C₂₁H₂₀N₄O₃
CAS No.	209783-80-2
Smiles	Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1
密度	1.315 g/cm3

产品组分

内容	型号	规格	储存温度
恩替诺特	T6233-01	10mg	-20°C
恩替诺特	T6233-02	50mg	-20°C
恩替诺特	T6233-03	100mg	-20°C
恩替诺特	T6233-04	500mg	-20°C
恩替诺特	T6233-05	1mLx10mM in DMSO	-20°C
操作手册	1	1	常温

文件资源

营销中心
注意事项

保存建议厂家推荐蓝冰运输。当您收到产品后，按照说明书建议保存于-20°C。
FAQ
1.Beckers T, et al. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer. 2007 Sep 1;121(5):1138-48.

2.Ma YT, et al. Use of a genome-wide haploid genetic screen to identify treatment predicting factors: a proof-of-principle study in pancreatic cancer. Oncotarget. 2017 Jun 29;8(38):63635-63645.

3.Saito A, et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4592-7.

4.Zhang ZY, et al. MS-275, an histone deacetylase inhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis. Neuroscience. 2010 Aug 11;169(1):370-7.

5.Moreno-Yruela C, Zhang D, Wei W, et al. Class I Histone Deacetylases (HDAC1‒3) are Histone Lysine Delactylases[J]. bioRxiv. 2021

6.Wellinger L C, Hogg S J, Newman D M, et al. BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity[J]. bioRxiv. 2021

7.Lagosz K B, Bysiek A, Macina J M, et al. HDAC3 Regulates Gingival Fibroblast Inflammatory Responses in Periodontitis[J]. Journal of dental research. 2019: 0022034519885088.